NeuroHealing Pharmaceuticals Inc.

	Repurposing Neurologically Active Compounds NeuroHealing is a clinical stage biopharmaceutical company developing innovative drug treatments for specialty indications based on neurologically active compounds.


PRODUCT PIPELINE NH001 Dopaminergic agent to help post-TBI patients to emerge from a coma, vegetative state or minimally conscious state. NH004 anticholinergic agent in an intra-orally muco-adhesive dissolving film for sialorrhea symptoms in patients motor neuron disease. NH02D neurologically active, novel-mechanism compound to treat premature ejaculation. Enter text here NH001 - Vegetative State/MCS Enter text here NH004 - Sialorrhea Enter text here NH02D - Premature Ejaculation

June 9, 2009
NH004 Sialorrhea Interim Results to be Presented at MDS '09
Interim results show dose-dependent decrease in drooling in Parkinson’s patients

April 13, 2009
NeuroHealing to Present NH02D Data on Premature Ejaculation at AUA
Preclinical study shows positive effect of acute NH02D administration for treatment of premature ejaculation

February 24, 2009
Brain Injury Publishes Report of Fast Awakening from MCS with NH001
After 104 days in minimally conscious state (MCS), patient regains consciousness within 24 hours of NH001 infusion

February 2, 2009
David Gwynne, Ph.D., Appointed as VP Business Development
Dr. Gwynne to initially focus on finding partners/investors for NH02D premature ejaculation program

September 24, 2008
NeuroHealing to Present at Drug Repositioning Summit
Neal Farber, CEO, to present: "There's still low hanging fruit: three repositioned drugs in clinical testing for brain injury patients"